These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1326 related articles for article (PubMed ID: 35345417)

  • 21. Immunological insights into COVID-19 in Southern Nigeria.
    Ugwu CA; Alao O; John OG; Akinnawo B; Ajayi I; Odebode O; Bejide I; Campbell A; Campbell J; Adole JA; B Olawoye I; Akano K; Okolie J; Eromon P; Olaitan P; Olagunoye A; Adebayo I; Adebayo V; Babalola E; Abioye O; Ajayi N; Ogah E; Ukwaja K; Okoro S; Oje O; Kingsley OC; Eke M; Onyia V; Achonduh-Atijegbe O; Ewah FE; Obasi M; Igwe V; Ayodeji O; Chukwuyem A; Owhin S; Oyejide N; Abah S; Ingbian W; Osoba M; Alebiosu A; Nadesalingam A; Aguinam ET; Carnell G; Krause N; Chan A; George C; Kinsley R; Tonks P; Temperton N; Heeney J; Happi C
    Front Immunol; 2024; 15():1305586. PubMed ID: 38322252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.
    Vangeti S; Periasamy S; Sun P; Balinsky CA; Mahajan AS; Kuzmina NA; Soares-Schanoski A; Cooper E; Beckett C; Marayag J; Marrone A; Nunez E; Ge Y; Porter CK; Goforth CW; Lizewski SE; Lizewski R; Jani V; Sugiharto VA; Schilling M; Yu XB; Marjanovic N; George MC; Bukreyev A; Sealfon SC; Letizia AG; Ramos I
    Microbiol Spectr; 2022 Dec; 10(6):e0183722. PubMed ID: 36374040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
    Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
    Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
    Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
    Front Immunol; 2021; 12():748291. PubMed ID: 34867975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
    Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Mikkelsen LS; Fahnøe U; Bollerup S; Winckelmann AA; Schneider UV; Binderup A; Vizgirda G; Sørensen AL; Vinten CN; Dalegaard MI; Ramirez S; Weis N; Bukh J
    EBioMedicine; 2023 Mar; 89():104475. PubMed ID: 36870117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan.
    Masood KI; Qaiser S; Abidi SH; Khan E; Mahmood SF; Hussain A; Ghous Z; Imtiaz K; Ali N; Hasan M; Memon HA; Yameen M; Ali S; Baloch S; Lakhani G; Alves PM; Iqbal NT; Ahmed K; Iqbal J; Bhutta ZA; Hussain R; Rottenberg M; Simas JP; Veldhoen M; Ghias K; Hasan Z
    BMC Infect Dis; 2023 Dec; 23(1):846. PubMed ID: 38041026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
    Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Khan H; Lechmere T; Malim MH; Meynell F; Pollock E; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree T; Smith CH
    Lancet Rheumatol; 2022 Jan; 4(1):e42-e52. PubMed ID: 34778846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
    Liew F; Talwar S; Cross A; Willett BJ; Scott S; Logan N; Siggins MK; Swieboda D; Sidhu JK; Efstathiou C; Moore SC; Davis C; Mohamed N; Nunag J; King C; Thompson AAR; Rowland-Jones SL; Docherty AB; Chalmers JD; Ho LP; Horsley A; Raman B; Poinasamy K; Marks M; Kon OM; Howard L; Wootton DG; Dunachie S; Quint JK; Evans RA; Wain LV; Fontanella S; de Silva TI; Ho A; Harrison E; Baillie JK; Semple MG; Brightling C; Thwaites RS; Turtle L; Openshaw PJM; ;
    EBioMedicine; 2023 Jan; 87():104402. PubMed ID: 36543718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
    Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China.
    Yang Y; Guo L; Yuan J; Xu Z; Gu Y; Zhang J; Guan Y; Liang J; Lu H; Liu Y
    Lancet Microbe; 2023 Aug; 4(8):e632-e641. PubMed ID: 37459867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.
    Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
    Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
    Jeffery-Smith A; Rowland TAJ; Patel M; Whitaker H; Iyanger N; Williams SV; Giddings R; Thompson L; Zavala M; Aiano F; Ellis J; Lackenby A; Höschler K; Brown K; Ramsay ME; Gopal R; Chow JY; Ladhani SN; Zambon M
    Lancet Healthy Longev; 2021 Dec; 2(12):e811-e819. PubMed ID: 34873592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.
    Sherina N; Piralla A; Du L; Wan H; Kumagai-Braesch M; Andréll J; Braesch-Andersen S; Cassaniti I; Percivalle E; Sarasini A; Bergami F; Di Martino R; Colaneri M; Vecchia M; Sambo M; Zuccaro V; Bruno R; Sachs M; Oggionni T; Meloni F; Abolhassani H; Bertoglio F; Schubert M; Byrne-Steele M; Han J; Hust M; Xue Y; Hammarström L; Baldanti F; Marcotte H; Pan-Hammarström Q
    Med; 2021 Mar; 2(3):281-295.e4. PubMed ID: 33589885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.
    Hvidt AK; Guo H; Andersen R; Lende SSF; Vibholm LK; Søgaard OS; Schleimann MH; Russell V; Cheung AM; Paramithiotis E; Olesen R; Tolstrup M
    BMC Immunol; 2023 Nov; 24(1):45. PubMed ID: 37974069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD
    J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis.
    Meyer B; Martinez-Murillo PA; Lemaitre B; Blanchard-Rohner G; Didierlaurent AM; Fontannaz P; Eugercios Manzanas C; Lambert PH; Loevy N; Kaiser L; Sartoretti J; Tougne C; Villard J; Huttner A; Siegrist CA; Eberhardt CS
    Front Immunol; 2022; 13():841009. PubMed ID: 35585978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
    Masiá M; Fernández-González M; García JA; Padilla S; García-Abellán J; Botella Á; Mascarell P; Agulló V; Gutiérrez F
    EBioMedicine; 2022 Aug; 82():104153. PubMed ID: 35816896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
    Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
    PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
    Souza WM; Amorim MR; Sesti-Costa R; Coimbra LD; Brunetti NS; Toledo-Teixeira DA; de Souza GF; Muraro SP; Parise PL; Barbosa PP; Bispo-Dos-Santos K; Mofatto LS; Simeoni CL; Claro IM; Duarte ASS; Coletti TM; Zangirolami AB; Costa-Lima C; Gomes ABSP; Buscaratti LI; Sales FC; Costa VA; Franco LAM; Candido DS; Pybus OG; de Jesus JG; Silva CAM; Ramundo MS; Ferreira GM; Pinho MC; Souza LM; Rocha EC; Andrade PS; Crispim MAE; Maktura GC; Manuli ER; Santos MNN; Camilo CC; Angerami RN; Moretti ML; Spilki FR; Arns CW; Addas-Carvalho M; Benites BD; Vinolo MAR; Mori MAS; Gaburo N; Dye C; Marques-Souza H; Marques RE; Farias AS; Diamond MS; Faria NR; Sabino EC; Granja F; Proença-Módena JL
    Lancet Microbe; 2021 Oct; 2(10):e527-e535. PubMed ID: 34258603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.